CD274 and neoplasm: Previous studies have suggested that the expression level of PD-L1 in tumor cells (12), tumor mutation burden (TMB) (13), microsatellite instability (MSI) (14, 15), and tumor-specific antigens (TSAs) (16) can serve as biomarkers to predict the efficacy of immunotherapy for lung cancer.